| 1 |
Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil 2023;:e14539. [PMID: 36740814 DOI: 10.1111/nmo.14539] [Reference Citation Analysis]
|
| 2 |
Jones MP, Holtmann G. Placebo effects in functional dyspepsia: Causes and implications for clinical trials. Neurogastroenterol Motil 2023;35:e14527. [PMID: 36592054 DOI: 10.1111/nmo.14527] [Reference Citation Analysis]
|
| 3 |
Lembo A, Kuo B, Boinpally R, Li E, Mallick M, Bochenek W, Bartolini W. Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2023;57:192-204. [PMID: 36324245 DOI: 10.1111/apt.17274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Jones MP, Guthrie-Lyons L, Sato YA, Talley NJ. Factors Associated With Placebo Treatment Response in Functional Dyspepsia Clinical Trials. Am J Gastroenterol 2022. [PMID: 36729385 DOI: 10.14309/ajg.0000000000002097] [Reference Citation Analysis]
|
| 5 |
Pessarelli T, Sorge A, Elli L, Costantino A. The low-FODMAP diet and the gluten-free diet in the management of functional abdominal bloating and distension. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1007716] [Reference Citation Analysis]
|
| 6 |
Staller K, Paz M, Rones R, Macklin EA, Garcia-Fischer I, Murray HB, Kuo B. Virtual Tai Chi program for patients with irritable bowel syndrome with constipation: Proof-of-concept feasibility trial. Neurogastroenterol Motil 2022;34:e14429. [PMID: 35833716 DOI: 10.1111/nmo.14429] [Reference Citation Analysis]
|
| 7 |
Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522 [DOI: 10.3748/wjg.v28.i22.2509] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Singh P, Ballou S, Rangan V, Katon J, Hassan R, Iturrino J, Lembo A, Nee J. Clinical and Psychological Factors Predict Outcome in Patients With Functional Dyspepsia: A Prospective Study. Clin Gastroenterol Hepatol 2022;20:1251-1258.e1. [PMID: 34339874 DOI: 10.1016/j.cgh.2021.07.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Shah ED, Brenner DM, Chen VL. Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System. Dig Dis Sci 2022;67:1213-21. [PMID: 33779879 DOI: 10.1007/s10620-021-06963-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Rangan V, Singh P, Ballou S, Hassan R, Yu V, Katon J, Nee J, Iturrino J, Lembo A. Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders. Neurogastroenterol Motil 2022;34:e14253. [PMID: 34520617 DOI: 10.1111/nmo.14253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 11 |
Woźniak M, Fabisiak A, Talar-wojnarowska R, Małecka-wojciesko E. The effect of curcumin on symptoms and quality of life in patients with irritable bowel syndrome. Postępy Higieny i Medycyny Doświadczalnej 2022;76:345-350. [DOI: 10.2478/ahem-2022-0048] [Reference Citation Analysis]
|
| 12 |
Benson S, Theysohn N, Kleine-Borgmann J, Rebernik L, Icenhour A, Elsenbruch S. Positive Treatment Expectations Shape Perceived Medication Efficacy in a Translational Placebo Paradigm for the Gut-Brain Axis. Front Psychiatry 2022;13:824468. [PMID: 35401247 DOI: 10.3389/fpsyt.2022.824468] [Reference Citation Analysis]
|
| 13 |
Shah ED, Chang L, Lembo A, Staller K, Curley MA, Chey WD. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. Dig Dis Sci 2021;66:4140-8. [PMID: 33433804 DOI: 10.1007/s10620-020-06806-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 14 |
Flowers KM, Patton ME, Hruschak VJ, Fields KG, Schwartz E, Zeballos J, Kang JD, Edwards RR, Kaptchuk TJ, Schreiber KL. Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial. Pain 2021;162:1828-39. [PMID: 33449503 DOI: 10.1097/j.pain.0000000000002185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 15 |
Shah ED. Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2021;6:416-7. [PMID: 33765446 DOI: 10.1016/S2468-1253(21)00056-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis. MDM Policy Pract 2021;6:2381468320978417. [PMID: 33521290 DOI: 10.1177/2381468320978417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Nee J, Salley K, Ludwig AG, Sommers T, Ballou S, Takazawa E, Duehren S, Singh P, Iturrino J, Katon J, Lee HN, Rangan V, Lembo AJ. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Clin Transl Gastroenterol 2019;10:e00110. [PMID: 31800542 DOI: 10.14309/ctg.0000000000000110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 18 |
Hall KT, Vase L, Tobias DK, Dashti HT, Vollert J, Kaptchuk TJ, Cook NR. Historical Controls in Randomized Clinical Trials: Opportunities and Challenges. Clin Pharmacol Ther 2021;109:343-51. [PMID: 32602555 DOI: 10.1002/cpt.1970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Botelho PB, Ferreira MVR, Araújo AM, Mendes MM, Nakano EY. Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: A double-blind, placebo-controlled randomized trial. Nutrition 2020;78:110890. [PMID: 32738573 DOI: 10.1016/j.nut.2020.110890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 20 |
Kaptchuk TJ, Hemond CC, Miller FG. Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ 2020;370:m1668. [PMID: 32690477 DOI: 10.1136/bmj.m1668] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 21 |
Chateau T, Le Berre C, Peyrin-Biroulet L. Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases? Clin Gastroenterol Hepatol 2020;18:1030-2. [PMID: 31589974 DOI: 10.1016/j.cgh.2019.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 22 |
Lembo AJ, Covington PS, Dove LS, Andrae DA. Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials. Neurogastroenterol Motil 2020;32:e13774. [PMID: 31984655 DOI: 10.1111/nmo.13774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 23 |
Enck P, Klosterhalfen S. Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders. Front Psychiatry 2020;11:797. [PMID: 33192627 DOI: 10.3389/fpsyt.2020.00797] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 24 |
Nee J, Sugarman MA, Ballou S, Katon J, Rangan V, Singh P, Zubiago J, Kaptchuk TJ, Lembo A. Placebo Response in Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:1838-46. [PMID: 31592782 DOI: 10.14309/ajg.0000000000000399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 25 |
Ballou S. Reply. Clin Gastroenterol Hepatol 2019;17:1216. [PMID: 30639777 DOI: 10.1016/j.cgh.2019.01.003] [Reference Citation Analysis]
|
| 26 |
Palmer RH. Predictors of the Placebo Response in Irritable Bowel Syndrome With Constipation. Clin Gastroenterol Hepatol 2019;17:1215-6. [PMID: 30583047 DOI: 10.1016/j.cgh.2018.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
